These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 29608409)

  • 1. Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine.
    Malcolm BJ; Polanco M; Barsuglia JP
    J Psychoactive Drugs; 2018; 50(3):256-265. PubMed ID: 29608409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification.
    Davis AK; Renn E; Windham-Herman AM; Polanco M; Barsuglia JP
    J Psychoactive Drugs; 2018; 50(4):287-297. PubMed ID: 30020025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.
    Noller GE; Frampton CM; Yazar-Klosinski B
    Am J Drug Alcohol Abuse; 2018; 44(1):37-46. PubMed ID: 28402682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.
    Brown TK; Alper K
    Am J Drug Alcohol Abuse; 2018; 44(1):24-36. PubMed ID: 28541119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acute opioid withdrawal with ibogaine.
    Alper KR; Lotsof HS; Frenken GM; Luciano DJ; Bastiaans J
    Am J Addict; 1999; 8(3):234-42. PubMed ID: 10506904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder.
    Brown TK; Noller GE; Denenberg JO
    J Psychoactive Drugs; 2019; 51(2):155-165. PubMed ID: 30967101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single high-dose buprenorphine for opioid craving during withdrawal.
    Ahmadi J; Jahromi MS; Ghahremani D; London ED
    Trials; 2018 Dec; 19(1):675. PubMed ID: 30526648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of anxiety sensitivity on opioid use disorder treatment outcomes.
    Baxley C; Weinstock J; Lustman PJ; Garner AA
    Exp Clin Psychopharmacol; 2019 Feb; 27(1):64-77. PubMed ID: 30080059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes.
    Mash DC; Duque L; Page B; Allen-Ferdinand K
    Front Pharmacol; 2018; 9():529. PubMed ID: 29922156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.
    Knuijver T; Ter Heine R; Schellekens AFA; Heydari P; Lucas L; Westra S; Belgers M; van Oosteren T; Verkes RJ; Kramers C
    J Psychopharmacol; 2024 May; 38(5):481-488. PubMed ID: 38519421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report.
    Cloutier-Gill L; Wood E; Millar T; Ferris C; Eugenia Socias M
    J Psychoactive Drugs; 2016; 48(3):214-7. PubMed ID: 27192438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of pain impact and sleep disruption with opioid withdrawal during opioid-use disorder treatment.
    Ellis JD; Han D; Mayo J; Hobelmann JG; Finan PH; Huhn AS
    Br J Clin Pharmacol; 2024 Jun; 90(6):1408-1417. PubMed ID: 38417973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: A double-blind randomized clinical trial in Singapore.
    Guo S; Manning V; Yang Y; Koh PK; Chan E; de Souza NN; Assam PN; Sultana R; Wijesinghe R; Pangjaya J; Kandasami G; Cheok C; Lee KM; Wong KE
    J Subst Abuse Treat; 2018 Aug; 91():1-11. PubMed ID: 29910009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of synthetic cannabinoids on the duration of opioid-related withdrawal and craving among patients of addiction clinics in Kazakhstan: A prospective case-control study.
    Prilutskaya M; Bersani FS; Corazza O; Molchanov S
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28631421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of withdrawal symptoms during opioid detoxification.
    Dijkstra BA; Krabbe PF; De Jong CA; van der Staak CP
    J Opioid Manag; 2008; 4(5):311-9. PubMed ID: 19070269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of withdrawal in mesocorticolimbic drug cue reactivity in opioid use disorder.
    Shi Z; Jagannathan K; Padley JH; Wang AL; Fairchild VP; O'Brien CP; Childress AR; Langleben DD
    Addict Biol; 2021 Jul; 26(4):e12977. PubMed ID: 33098179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between craving, anxiety, and other symptoms in opioid withdrawal.
    Swift RM; Stout RL
    J Subst Abuse; 1992; 4(1):19-26. PubMed ID: 1320971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic literature review of clinical trials and therapeutic applications of ibogaine.
    Köck P; Froelich K; Walter M; Lang U; Dürsteler KM
    J Subst Abuse Treat; 2022 Jul; 138():108717. PubMed ID: 35012793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IUPHAR - invited review - Ibogaine - A legacy within the current renaissance of psychedelic therapy.
    Mash DC
    Pharmacol Res; 2023 Apr; 190():106620. PubMed ID: 36907284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of gabapentin dose in treatment of opioid withdrawal.
    Salehi M; Kheirabadi GR; Maracy MR; Ranjkesh M
    J Clin Psychopharmacol; 2011 Oct; 31(5):593-6. PubMed ID: 21869694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.